Rikkunshito for Dyspepsia: Four Trial Checks
Bloating & DigestionArticleThe Suzuki study did not establish an overall symptom benefit.

In this article
If you are considering rikkunshito for persistent upper-abdominal symptoms, take the exact packet and your medicine list to a clinician or pharmacist. Include other herbal products, teas and powders. Discuss the diagnosis, the result you hope to achieve and a review date before buying another product.
Check the overall result
Suzuki’s Japanese trial randomized 247 adults, including 156 women, to rikkunshito or placebo for eight weeks. Participants had investigated functional dyspepsia; structural disease and heartburn within the previous twelve weeks were excluded.1
The primary result was 42/125 versus 29/122 reporting improvement or extreme improvement in overall symptoms. The difference was not statistically significant (P=.09). This does not establish overall benefit or prove no effect.1
Separate other findings
Recruitment stopped below the original 430-person target, reducing statistical power. The revised target assumed only 50% power. A secondary upper-abdominal-pain result favored rikkunshito (P=.04), but numerous comparisons lacked a stated multiplicity adjustment. That finding does not turn the primary comparison positive. Japan’s health ministry funded the trial; authors disclosed industry relationships. A separate per-protocol analysis excluded discontinuations and missing questionnaires, leaving 207 people.1
The Asian consensus published in February 2026 says traditional or integrative medicines should be selected according to evidence, availability and the healthcare system. It grades that recommendation’s evidence as moderate and encourages further research. A regional recommendation does not make every product sold under a similar name interchangeable.2
Identify the exact product
The trial report did not name a commercial brand.1
Japan’s current Tsumura medical-use rikkunshito label describes a specified herbal extract containing licorice, or Glycyrrhiza. Its indications include indigestion, poor appetite and stomach pain in a defined constitutional symptom pattern. This is a Japanese product label, not authorization for any imported supplement or homemade blend. Ask which formulation is being considered and which local rules apply.3
The consensus also recommends eradication treatment for dyspepsia with proven H. pylori infection. Ask whether testing or treatment is relevant to your assessment. An herbal product should not be used to defer care for a confirmed infection.2
Plan monitoring
The Japanese label warns about low potassium, raised blood pressure and fluid retention, a syndrome called pseudoaldosteronism. Low potassium can cause muscle problems; liver injury and jaundice are also listed serious adverse effects. Other products containing licorice or glycyrrhizin can increase the risk. Bring all products to the medication review.3
The label calls for attention to potassium and blood pressure and advises avoiding continued treatment without improvement. Agree how benefit and unwanted effects will be checked.3
Bloated by Dinner includes “The Visit Script,” which asks you to record symptom timing and list medicines and supplements, including teas and powders. It also provides two appointment questions: what has been ruled out, and what happens next? Use that preparation when discussing an unfamiliar treatment.
This article is educational and does not replace advice from your clinician or pharmacist. Trial treatments describe research, not instructions to start an herbal medicine or change existing treatment.
Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.
Sources
The research behind this article, in the order it’s cited. How we source our articles.
- Suzuki and colleagues, Neurogastroenterology & Motility, 2014Rikkunshito for functional dyspepsia: randomized placebo-controlled trial (opens in a new tab)abcd
- Asian Neurogastroenterology and Motility Association and APAGE, Published February 2026Second Asian consensus on functional dyspepsia: statements 22 and 31 (opens in a new tab)ab
- Pharmaceuticals and Medical Devices Agency, Japan, Revised December 2023; checked October 2026Tsumura Rikkunshito Extract Granules for Medical Use: current label (opens in a new tab)abc
Spotted something out of date? Tell us and we’ll check it.


